Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer

Gastric Cancer

Volumn 13, Issue 3, 2010, Pages 186-190

  Takahari, Daisuke ^a,b   Shimada, Yasuhiro ^a   Takeshita, Shigeyuki ^a   Nishitani, Hitoshi ^a   Takashima, Atsuo ^a   Okita, Natsuko ^a   Hirashima, Yoshinori ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Yamada, Yasuhide ^a   Shirao, Kuniaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cisplatin; Gastric cancer; Irinotecan; S 1 failure; Second line chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; IRINOTECAN; MITOMYCIN C; PACLITAXEL;

ACNE; ADULT; ADVANCED CANCER; AGED; ANAPHYLACTIC SHOCK; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT REFUSAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OXONIC ACID; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR; TIME FACTORS; TREATMENT FAILURE;

EID: 77957964500     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-010-0557-0     Document Type: Article

References (16)

1. N. Boku S. Yamamoto H. Fukuda K. Shirao T. Doi A. Sawaki, et al. 2009 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063 1069 1:CAS:528:DC%2BD1MXhtlGit7bI 10.1016/S1470-2045(09)70259-1 19818685
2. W. Koizumi H. Narahara T. Hara A. Takagane T. Akiya M. Takagi, et al. 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 1:CAS:528:DC%2BD1cXivVaqtb4%3D 10.1016/S1470-2045(08)70035-4 18282805
3. Imamura H, Iiishi H, Tsuburaya A, Hatake K, Imamoto H, Esaki T, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP002). Gastrointestinal Cancers Symposium 2008:abstract 5.
4. S. Sakuramoto M. Sasako T. Yamaguchi T. Kinoshita M. Fujii A. Nashimoto, et al. 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 1820 1:CAS:528:DC%2BD2sXht1Kit7bI 10.1056/NEJMoa072252 17978289 (Pubitemid 350044801)
5. T. Hamaguchi A. Ohtsu I. Hyodo Y. Arai H. Takiuchi H. Fujii, et al. 2004 A phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: The Japan Clinical Oncology Group trial (JCOG0109) J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22 14S 4071
6. F. Giuliani S. Molica E. Maiello C. Battaglia V. Gebbia M. Di Bisceglie, et al. 2005 Irinotecan (CPT-11) and mitomycin-C (MMC) as secondline therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106) Am J Clin Oncol 28 581 585 1:CAS:528: DC%2BD28Xit12jsA%3D%3D 10.1097/01.coc.0000190398.52142.7f 16317268 (Pubitemid 41790010)
7. K. Futatsuki A. Wakui I. Nakao Y. Sakata M. Kambe Y. Shimada, et al. 1994 Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer Gan To Kagaku Ryoho 21 1033 1038 1:STN:280:DyaK2c3ntVyisg%3D%3D 8210254 (Pubitemid 24225031)
8. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2009;27:(Suppl;abstract 4540).
9. N. Boku A. Ohtsu Y. Shimada K. Shirao S. Seki H. Saito, et al. 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319 323 1:CAS:528:DyaK1MXltVyrtg%3D%3D 10458249
10. J.A. Ajani J. Baker P.W. Pisters L. Ho P.F. Mansfield B.W. Feig, et al. 2002 Irinotecan/cisplatin in advanced, treated gastric or gastroesopha geal junction carcinoma Oncology (Williston Park) 16 16 18
11. S. Ueda S. Hironaka N. Boku A. Fukutomi T. Yoshino Y. Onozawa 2006 Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer Gastric Cancer 9 203 207 1:CAS:528:DC%2BD28XptVeqsrs%3D 10.1007/s10120-006-0379-2 16952039 (Pubitemid 44426894)
12. W. Koizumi M. Kurihara A. Satoh H. Takiuchi S. Tanabe K. Shimada, et al. 2005 Phase I/II study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer Anticancer Res 25 1257 1262 1:CAS:528: DC%2BD2MXkt1Wnur0%3D 15865075 (Pubitemid 40546799)
13. S. Nakae M. Hirao T. Kishimoto S. Iijima H. Ishida T. Morimoto, et al. 2008 Phase II study of bi-weekly CPT-11+CDDP for patients with gastric cancer refractory to S-1 (OGSG 0504 study) J Clin Oncol, 2008 ASCO Annual Meeting Proceedings 2615S 4571
14. Arai T, Hamaguchi T, Shirao K, Shimada Y, Yamada Y, Muro K, et al. Weekly paclitaxel in patients with heavily treated advanced gastric cancer. Proc Am Soc Clin Oncol 2003;22 Abstract 1291.
15. S. Hironaka S. Zenda N. Boku A. Fukutomi T. Yoshino Y. Onozawa 2006 Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer Gastric Cancer 9 14 18 1:CAS:528:DC%2BD28XivVeguro%3D 10.1007/s10120-005-0351-6 16557431
16. J.C. Jo J.L. Lee M.H. Ryu S.J. Sym S.S. Lee H.M. Chang, et al. 2007 Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis Jpn J Clin Oncol 37 936 941 10.1093/jjco/hym123 18211985 (Pubitemid 351176485)